[Status of glitazones in treatment of type 2 diabetes mellitus].
Willeke
A
A
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D019468:Disease Management; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005858:Germany; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D008134:Long-Term Care; D008687:Metformin / Q000627:therapeutic use; D000077205:Pioglitazone; D017410:Practice Guidelines as Topic; D016019:Survival Analysis; D045162:Thiazolidinediones / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D008687:Metformin; D005905:Glyburide; D000077205:Pioglitazone